Get the Stockscreener App
107.64
0.75%
0.805
Kymera Therapeutics Inc stock is traded at $107.64, with a volume of 196.58K.
It is up +0.75% in the last 24 hours and down -4.87% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
See More
Previous Close:
$106.83
Open:
$106.75
24h Volume:
196.58K
Relative Volume:
0.21
Market Cap:
$8.95B
Revenue:
$51.48M
Net Income/Loss:
$-315.00M
P/E Ratio:
-30.14
EPS:
-3.5708
Net Cash Flow:
$-244.00M
1W Performance:
-1.52%
1M Performance:
-4.87%
6M Performance:
+20.94%
1Y Performance:
+71.15%
1-Day Range:
$104.62
$110.68
1-Week Range:
$105.58
$115.81
52-Week Range:
$55.26
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
107.64 | 8.95B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
509.74 | 129.20B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.26 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.01 | 53.39B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-26 | Initiated | Raymond James | Outperform |
| Sep-10-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-30-26 | Initiated | Deutsche Bank | Hold |
| May-06-26 | Initiated | Canaccord Genuity | Buy |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-03-25 | Resumed | Guggenheim | Buy |
| Oct-24-25 | Reiterated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-18-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jun-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-02-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-20-25 | Resumed | Stifel | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock Has Average Target Price of $134.68 - MarketBeat
Form 4 Kymera Therapeutics Inc For: 1 October By Investing.com - Investing.com Nigeria
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock - Investing.com
Form 4 Kymera Therapeutics Inc For: 1 October By Investing.com - Investing.com India
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock By Investing.com - Investing.com UK
After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. - Stock Titan
A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. - Stock Titan
Kymera Therapeutics (NasdaqGM:KYMR) Stock Forecast & Analyst Predictions - Simply Wall Street
Bank of America Corp DE Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc.Common Stock (Nasdaq:KYMR) Price Chart - The Chronicle-Journal
Understanding Momentum Shifts in (KYMR) - Stock Traders Daily
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Canada
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com India
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com Australia
KYMR Upgraded by Wolfe Research -- Rating Raised to Outperform - GuruFocus
Squarepoint Ops LLC Raises Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com South Africa
Kymera Therapeutics at Wells Fargo conference: oral pipeline gains pace By Investing.com - Investing.com Canada
Fund giant T. Rowe Price holds a double-digit stake in Kymera (KYMR) - Stock Titan
Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - MarketBeat
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Nigeria
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Australia
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Canada
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com
Kymera Therapeutics (NASDAQ:KYMR) Insider Brian Adams Sells 6,371 Shares of Stock - MarketBeat
Kymera (NASDAQ: KYMR) insider plans stock sale to cover taxes - Stock Titan
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - The Globe and Mail
Can KT-621 Mark a Turning Point for Kymera Therapeutics? - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Braidwell LP Buys 40,604 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
21,058 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Jupiter Topco LLC - MarketBeat
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Executive at Kymera Therapeutics (NASDAQ: KYMR) plans another stock sale after June trade of $4.4M - Stock Titan
Kymera Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net
Five September events will webcast Kymera live - Stock Titan
Man Group plc Makes New $2.19 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - investingnews.com
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses - marketscreener.com
A clinical trial testing an oral medicine for eczema has finished enrolling patients. Kymera expects topline data by year-end 2026. - Stock Titan
Kymera Therapeutics (NASDAQ:KYMR) Gains on Higher Price Target - Kalkine Media
KYMR Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Given New $170.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Kymera Therapeutics price target to $170 on STAT6 program - Investing.com Nigeria
Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Alyeska Investment Group L.P. - MarketBeat
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kymera Therapeutics Inc Stock (KYMR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mainolfi Nello | Officer |
Oct 01 '26 |
Proposed Sale |
111.79 |
30,000 |
3,353,700 |
0 |
| Mainolfi Nello | Chief Executive Officer |
Oct 01 '26 |
Sale |
113.80 |
30,000 |
3,413,917 |
666,568 |
| Brian Adams | Officer |
Sep 04 '26 |
Proposed Sale |
117.28 |
6,371 |
747,191 |
0 |
| Adams Brian | Chief Legal Officer |
Sep 04 '26 |
Sale |
116.83 |
6,371 |
744,297 |
50,254 |
| JEREMY CHADWICK | Officer |
Sep 02 '26 |
Proposed Sale |
119.05 |
10,879 |
1,295,145 |
0 |
| Mainolfi Nello | Chief Executive Officer |
Jul 07 '26 |
Option Exercise |
2.08 |
50,000 |
104,000 |
716,568 |
| Mainolfi Nello | Officer |
Jul 07 '26 |
Proposed Sale |
119.00 |
50,000 |
5,950,000 |
0 |
| Mainolfi Nello | Chief Executive Officer |
Jul 07 '26 |
Sale |
119.00 |
50,000 |
5,950,000 |
666,568 |
| Mainolfi Nello | Chief Executive Officer |
Jul 01 '26 |
Sale |
115.29 |
80,000 |
9,223,527 |
666,568 |
| Mainolfi Nello | Officer |
Jul 01 '26 |
Proposed Sale |
114.29 |
80,000 |
9,143,200 |
0 |
1.03%
3.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):